BackNeurocrine Biosciences Overview

Neurocrine Biosciences Goodwill

Track Neurocrine Biosciences's goodwill ($500M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Goodwill
$500.60M

Peer trimmed avg / median

Loading

Neurocrine Biosciences Goodwill History

Loading

Neurocrine Biosciences vs. peers: Goodwill Comparison

Loading

Neurocrine Biosciences Goodwill Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Neurocrine Biosciences (NBIX) FAQ

Neurocrine Biosciences's goodwill stands at $500M as of June 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Neurocrine Biosciences reported $500M in goodwill versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in goodwill can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Neurocrine Biosciences's goodwill evolved across reporting periods, while the comparison chart places NBIX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, goodwill is commonly used to spot outliers. Neurocrine Biosciences's reading of $500M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.